These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 24262196)

  • 1. Modeling Lewy pathology propagation in Parkinson's disease.
    Luk KC; Lee VM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S85-7. PubMed ID: 24262196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
    Uchihara T; Giasson BI
    Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease from the gut.
    Liddle RA
    Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.
    Seidel K; Mahlke J; Siswanto S; Krüger R; Heinsen H; Auburger G; Bouzrou M; Grinberg LT; Wicht H; Korf HW; den Dunnen W; Rüb U
    Brain Pathol; 2015 Mar; 25(2):121-35. PubMed ID: 24995389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
    Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
    Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation and development of Lewy pathology: a critical update.
    Jellinger KA
    J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spreading of alpha-synuclein - relevant or epiphenomenon?
    Killinger BA; Kordower JH
    J Neurochem; 2019 Sep; 150(5):605-611. PubMed ID: 31152606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
    Lashuel HA
    Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Lewy body in Parkinson's disease and related neurodegenerative disorders.
    Wakabayashi K; Tanji K; Odagiri S; Miki Y; Mori F; Takahashi H
    Mol Neurobiol; 2013 Apr; 47(2):495-508. PubMed ID: 22622968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity?
    Chartier S; Duyckaerts C
    Cell Tissue Res; 2018 Jul; 373(1):149-160. PubMed ID: 29869713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prion-like propagation of pathology in Parkinson disease.
    Volpicelli-Daley L; Brundin P
    Handb Clin Neurol; 2018; 153():321-335. PubMed ID: 29887143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
    Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
    Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.